Verzenio Tablet
Product Images NDC 0002-4815

Product Visual Gallery

This gallery contains 9 technical images submitted to the FDA as part of the official labeling for Verzenio (NDC 0002-4815). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Eli Lilly And Company, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Verzenio 100mg 14ct 031 01

Verzenio (abemaciclib) 100 mg tablets packaging label displaying a 7-day supply containing fourteen 100 mg tablets. The label includes instructions on how to take the tablets, urging users to take one 100 mg tablet twice daily, with guidance on swallowing and dosing adherence. The labeler is Lilly USA, LLC, and the product is marked as a human prescription drug. The package includes opening instructions and storage information with a barcode and National Drug Code (NDC 0002-4815-54).*

FDA Label Image

Verzenio 150mg 14ct 029 01

Verzenio (abemaciclib) 150 mg dose tablets carton label displaying a 7-day supply containing fourteen 150 mg tablets. The label includes dosing instructions, storage conditions, and manufacturer information for Eli Lilly and Company. It features a press-and-hold opening mechanism illustration and indicates it is a prescription drug with the NDC 0002-5337-54.*

FDA Label Image

Verzenio 200mg 14ct 027 01

Packaging label for Verzenio (abemaciclib) tablets 200 mg dose, containing 14 tablets for a 7-day supply. The label includes usage instructions, storage conditions, and manufacturer information: marketed by Lilly USA, LLC. The package shows how to open the dose pack by pressing and holding a button and pulling out the insert. The label notes the prescription status and indicates the tablets are oral dosage form.*

FDA Label Image

Verzenio 50mg 14ct 033 01

Verzenio (abemaciclib) tablets 50 mg dose pack containing fourteen tablets in a 7-day supply. The packaging includes instructions for taking Verzenio tablets twice daily, morning and evening, with guidance on swallowing and dosage consistency. Labeler information shows Eli Lilly and Company, and storage conditions are detailed. The pack features a push-button to open and pull-out insert instructions.*

FDA Label Image

Chemical Structure (Verzenio Pi Chem Struct V1)

Chemical structure of abemaciclib, the active ingredient in Verzenio tablets, showing the molecular arrangement and bonding of atoms including nitrogen, fluorine, and carbon atoms.*

FDA Label Image

Verzenio Pi F1 V3

A Kaplan-Meier curve depicting progression-free survival probability (%) over time in months for Verzenio (abemaciclib) plus NSAI versus placebo plus NSAI. The solid line represents Verzenio plus NSAI group (N=328), the dashed line represents placebo plus NSAI group (N=165). Numbers of patients at risk at specific time points are detailed below the graph.*

FDA Label Image

Verzenio Pi F2 V2

A Kaplan-Meier curve displaying progression-free survival probability (%) over time in months for two groups: VERZENIO plus fulvestrant and placebo plus fulvestrant. The graph shows survival decreasing over approximately 27 months. The number of patients at risk for each group is listed below the x-axis at multiple time points, with censored observations marked on the curves.*

FDA Label Image

Verzenio Pi F3 V1

A Kaplan-Meier survival curve chart showing survival probability (%) over time in months comparing Verzenio plus fulvestrant versus placebo plus fulvestrant. The solid line represents Verzenio plus fulvestrant (N=446), and the dashed line represents placebo plus fulvestrant (N=223). The chart includes censored observations and a table of patients at risk for both groups at various time points.*

FDA Label Image

Verzenio Pi F4 V1

A line graph depicting invasive disease-free survival probability (%) over time in months, comparing two patient groups: VERZENIO plus Tamoxifen or Aromatase Inhibitors (N=1017) and Tamoxifen or Aromatase Inhibitors alone (N=986). The graph includes censored observations and shows patient numbers at risk at various time points up to 45 months.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.